The first details of the long-awaited House Democrat plan to lower drug prices leaked out Monday night, with elements that have long been anathema to the biopharma industry and its supporters in Washington.

While the world digested the details Tuesday, however, biopharma investors didn’t seem fazed. Some individual companies saw shares dip, but the biopharma indices of the Nasdaq and New York Stock Exchange were both up slightly at Tuesday’s close. Full details of the proposal could come this week, according to the Washington Post.

In current form the House bill “stands no chance of passing the Senate,” wrote SVB… Read more »